A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

@article{Saag2009ADP,
  title={A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.},
  author={Michael S Saag and James Goodrich and Gerd F{\"a}tkenheuer and Bonaventura Clotet and Nathan N Clumeck and John Stephen Sullivan and Mike Westby and Elna van der Ryst and Howard B Mayer},
  journal={The Journal of infectious diseases},
  year={2009},
  volume={199 11},
  pages={1638-47}
}
BACKGROUND Maraviroc, a CCR5 antagonist, is active against R5 but not X4 or dual- or mixed-tropic strains of human immunodeficiency virus type 1 (HIV-1). A phase 2b study was conducted to determine the safety and efficacy of maraviroc in combination with optimized background therapy in treatment-experienced patients infected with dual- or mixed-tropic HIV-1. METHODS Treatment-experienced patients with an HIV-1 RNA level 5000 copies/mL who had received 3 classes of drugs and/or were infected… CONTINUE READING